Based on this hypothesis, in this study we considered exosomal mRNA expression of PD-L1 and IFN-γ, together with cfDNA-derived TML and radiomic features as a possible pool of predictive markers of response to the anti-PD-1 agents nivolumab and pembrolizumab in NSCLC. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.